The latest developments
Gilead says first data on Nimbus NASH candidate are positive
Gilead Sciences has the first proof-of-concept data for its novel drug...
Nimbus in full-on drug development partnership with Charles River
Computational drug discovery firm Nimbus Therapeutics has reached a...
Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into PhII NASH trial
Nimbus Therapeutics Announces $200 Million Milestone Payment from Gilead Sciences for Allosteric ACC Inhibitor Program in Non-alcoholic Steatohepatitis (NASH)
Gilead Sciences pads its NASH stash with potential $1.2B Nimbus Therapeutics deal
Gilead Sciences Pledges $1.2B to Acquire Nimbus Therapeutics Subsidiary
Nimbus Therapeutics Announces Global License Agreement with Genentech
Nimbus Therapeutics Raises $43M Series B Round, Plans Clinical Trials of NASH Drug
Pfizer joins a powerhouse syndicate backing $43M round for Nimbus
© 2013 LIGHTSTONE VENTURES